Value through Innovation04 February 2016

Stroke Prevention

At Boehringer Ingelheim, we provide innovative treatments for stroke (as well as its prevention in atrial fibrillation), deep vein thrombosis and pulmonary embolism, hypertension and myocardial infarction.

Please select one of the options below:

To see our products, click here:

Cardiovascular disease... a major global health problem and the leading cause of death worldwide. The term cardiovascular (CV) disease includes:

  • Myocardial infarction (also known as a heart attack, when the blood supply to part of the heart is interrupted)
  • Stroke (interruption of the blood supply to part of the brain or bleeding in the brain)
  • Hypertension (high blood pressure)
  • Deep vein thrombosis (formation of a blood clot within a deep vein, mostly commonly in the legs)
  • Pulmonary embolism (when a blood clot detaches and travels to the lungs)

Risk factors...
...for CV disease include old age, tobacco use, physical inactivity, an unhealthy diet, harmful use of alcohol, obesity, hypertension, and diabetes.

Boehringer Ingelheim is dedicated to improving cardiovascular care...

...through the provision of a wide range of treatments:

  • Stroke prevention in patients with non-valvular AF atrial fibrillation (SPAF) with a non-vitamin K oral anticoagulant (NOAC)
  • Thrombolysis of acute ischaemic stroke
  • Long-term treatment of hypertension
  • Fibrinolysis of acute ST-elevation myocardial infarction (STEMI)
  • Treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE)
  • Prevention of recurrent DVT or PE in patients who have previously suffered from one or both of these

...and through corporate social responsibility projects
such as the angels initiative, sponsored by Boehringer Ingelheim, which aims to help doctors in low- and middle-income countries to set up and optimise acute stroke networks with the support of local and international stroke societies.


We recognise that the Internet serves a global community. The pharmaceutical industry, however, is subject to country specific regulatory considerations, which affect the information we can provide on our products. In addition, the registration status of pharmaceutical products may not be the same in different regions of the world and the approved product labels may also differ according to country specific requirements.
Therefore, please check the registration details of this/these product(s) locally in order to get up-to-date information.

Cardiovascular Topics


Cardio-Vascular Television

Cardio-Vascular Television